Eluvia drug-eluting vascular stent system

Boston Scientific has announced results from sub-analyses of the Imperial clinical trial for the Eluvia Drug-Eluting Vascular Stent System. Read more


The Eluvia Drug-Eluting Vascular Stent

Boston Scientific

Boston Scientific’s recent FDA approval for the Eluvia Stent System may disrupt Cook Medical’s position in the US peripheral stents market, with Cook expected to face stronger competition trying to maintain a larger share of the market in the future. Read more

North America

Boston Scientific’s first polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe Read more


The Majestic clinical trial assessing Boston Scientific’s Eluvia drug-eluting vascular stent system reflected a primary patency rate of more than 96% Read more